Centers | ||
|
|
|
BLAVATNIK CENTER for Drug Discovery | UCSC Chemical Screening Center | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
The BLAVATNIK CENTER for Drug Discovery (BCDD) is a fully integrated center for translational research, based at Tel Aviv University, that comprises medicinal chemistry, biological target identification and computer-assisted drug design units under... Read more |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
JDRF & Novo Nordisk to Collaborate on Type 1 DiabetesJDRF and Novo Nordisk have entered into collaboration to develop new immunotherapies to treat Type 1 diabetes. The new partnership will be based out of Novo's newly opened Type 1 Diabetes R&D Center in Seattle. JDRF and Novo Nordisk will be... View all SDDCThe DDU is now leading the SDDC. The Structure-guided Drug Discovery Coalition (SDDC) is an international research coalition led by the Structural Genomics Consortium, based at McGill University, Canada. The mission of the SDDC is to contribute to... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
